Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265.
Oral semaglutide isn’t just a blood sugar story anymore. The SOUL randomized trial, now under the microscope in Diabetes Care, looked at how this research peptide shapes kidney outcomes for people with type 2 diabetes. Li S’s comment brings fresh eyes to the original findings, raising questions and highlighting opportunities for further research.
Diabetes Care
by Li S
“Comment on Mann et al. Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial. Diabetes Care 2026;49:257-265. Li S(1). Author information: (1)Department of Critical Care Medicine, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, China.”
What did the SOUL trial show? People with type 2 diabetes using oral semaglutide saw promising signals in kidney health markers. The study tracked changes in estimated glomerular filtration rate (eGFR) and albuminuria. Both are standard indicators of kidney function and damage. Early data suggest oral semaglutide may slow down or limit kidney decline in this population.
Key takeaway: semaglutide isn’t just about glucose control. Researchers are now looking at possible protective effects beyond diabetes management. That means more reasons to study how this peptide interacts with complex metabolic and renal pathways.
Li S’s commentary adds context:
Points out the need for longer-term data on kidney outcomes
Stresses that more granular analysis could reveal who benefits most
Suggests future research should nail down mechanisms behind these renal effects
For researchers, this is a call to action. There’s real momentum behind studying oral semaglutide for kidney health. Expect to see more studies digging into how it works, what populations get the most benefit, and how to optimize protocols. Sourcing high-quality research peptides for these kinds of projects? Check out the vendor directory.
The bottom line: oral semaglutide’s impact on kidney outcomes is an exciting frontier. The research community is just getting started.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.